SHMT2 and acute lymphoblastic leukemia: In summary, the combination of unbiased genome-wide screening identifying the one-carbon folate pathway as a dependency in T-ALL, as well as the preclinical efficacy of SHMT1 and SHMT2 inhibition using both chemical and genetic approaches, support further optimization of SHMT1/2 inhibitors.